Vandana Abramson
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC (NCT07016399) | Vandana Abramson | 2025-09-09 |
Track Vandana Abramson automatically
Every clearance here is in the API, with alerts when new ones post.